Skip to main content
SpringerLink
Log in

Direkte Thrombininhibitoren

Pharmakologie und Anwendung in der kardiovaskulären Anästhesie

Direct thrombin inhibitors

Pharmacology and application in cardiovascular anesthesia

  • Klinische Pharmakologie
  • Published:
Der Anaesthesist Aims and scope Submit manuscript

Zusammenfassung

Die Möglichkeiten der medikamentösen Antikoagulation werden zusehends vielfältiger. Im anästhesiologisch-intensivmedizinischen Bereich gilt es darüber hinaus spezielle Krankheitsbilder wie die Heparin-induzierte Thrombozytopenie (HIT) zu kennen, zu diagnostizieren und zu behandeln. Diese Arbeit liefert eine Übersicht über die Substanzgruppe der direkten Thrombininhibitoren (DTI) als alternative Antikoagulanzien bei HIT in Verbindung mit kardiovaskulären Erkrankungen. Beim Einsatz von DTI sind die Erfahrung und die richtige Dosis der Schlüssel zum Erfolg und entscheiden über die zwei Gesichter der Hämostase: Thrombose und Blutung.

Abstract

The options for drug-controlled anticoagulation are becoming noticeably more manifold. In the area of anaesthesiology and intensive care, there are furthermore special disease patterns, such as heparin-induced thrombocytopenia (HIT) to be known, diagnosed and treated. This article gives a review of the substance groups of the direct thrombin inhibitors (DTI) as alternative anticoagulants for HIT in combination with cardiovascular diseases. For the administration of DTIs, experience and the correct dose are the keys to success and are the deciding factors for the two sides of haemostasis: thrombosis and haemorrhagie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Bates S, Weitz J (2000) The mechanisms of action of thrombin inhibitors. J Invasive Cardiol 12: 27F–32F

    PubMed  Google Scholar 

  2. Kozek-Langenecker S, Mohammad S, Masaki T et al. (2000) Effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg 90: 808–812

    Article  PubMed  CAS  Google Scholar 

  3. Xiao Z, Theroux P (1998) Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97: 251–256

    PubMed  CAS  Google Scholar 

  4. Sarich T, Woltz M, Eriksson U (2003) Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 41: 557–564

    Article  PubMed  CAS  Google Scholar 

  5. Weitz J (2007) Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 5: S65–S67

    Article  Google Scholar 

  6. Eriksson BI, Dahl O, Buller HR et al. (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3: 103–111

    Article  PubMed  CAS  Google Scholar 

  7. Rydel T, Ravichandran K, Tulinsky A (1990) The structure of a complex of recombinant hirudin and human α-thrombin. Science 249: 277–280

    Article  PubMed  CAS  Google Scholar 

  8. Eichler P, Friesen H, Lubenow N et al. (2000) Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96: 2373–2378

    PubMed  CAS  Google Scholar 

  9. Greinacher A, Lubenow N, Eichler P (2003) Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108: 2062–2065

    Article  PubMed  CAS  Google Scholar 

  10. Veach S, Franks A, Allan M (2007) Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. Pharmacotherapy 27: 760–765

    Article  PubMed  CAS  Google Scholar 

  11. Maraganore JM, Bourdon P, Jablonski J et al. (1990) Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29: 7095–7101

    Article  PubMed  CAS  Google Scholar 

  12. Parry M, Maraganore J, Stone S (1994) Kinetic mechanism for the interaction of hirulog with thrombin. Biochemistry 33: 14807–14814

    Article  PubMed  CAS  Google Scholar 

  13. Robson R, White H, Aylward P, Frampton C (2002) Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin Pharmacol Ther 71: 433–439

    Article  PubMed  CAS  Google Scholar 

  14. Chew D, Bhatt D, Kimball W (2003) Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 92: 919–923

    Article  PubMed  CAS  Google Scholar 

  15. Lewis B, Hursting M (2004) Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia. Dekker, New York, pp 437–474

  16. Hauptmann J, Sturzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93: 203–241

    Article  PubMed  CAS  Google Scholar 

  17. Berry C, Girardot C, Lecroffre C, Lunven C (1994) Effect of synthetic thrombin inhibitor argatroban on fibrin- and clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72: 381–386

    PubMed  CAS  Google Scholar 

  18. Swan S, Hursting M (2000) The pharmacokinetics and pharmacodynamics of argatroban: effect of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20: 318–329

    Article  PubMed  CAS  Google Scholar 

  19. Walenga J, Ahmad S, Hoppensteadt D et al. (2002) Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105: 401–405

    Article  PubMed  CAS  Google Scholar 

  20. Chong B, Magnani H (2004) Danaparoid for the treatment of the heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia. Dekker, New York, pp 371–398

  21. Magnani HN, Gallus AS (2006) Heparin-induced thrombocytopenia (HIT). A report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95: 967–981

    PubMed  CAS  Google Scholar 

  22. Fenyvesi T, Jorg I, Harenberg J (2002) Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 28: 361–368

    Article  PubMed  CAS  Google Scholar 

  23. Clarke R, Mayo G, Fitzgerald G, Fitzgerald D (1991) Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 83: 1510–1518

    PubMed  CAS  Google Scholar 

  24. Moser M, Ruef J, Peter K (2001) Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J Thromb Thrombolysis 12: 165–169

    Article  PubMed  CAS  Google Scholar 

  25. Callas D, Hoppensteadt D, Iqbal O, Fareed J (1996) Ecarin clotting time (ECT) is a reliable method for the monitoring of hirudins, argatroban, efegatran and related drugs in therapeutic and cardiovascular indications(abstract). Ann Haematol 1: A58

    Google Scholar 

  26. Callas D, Fareed J (1996) Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 83: 463–468

    Article  PubMed  CAS  Google Scholar 

  27. Pötsch B, Madlener K (2004) Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia. Dekker, New York, pp 531–532

  28. Lindhoff-Last E, Piechotta G, Rabe F, Bauersachs R (2000) Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 100: 55–60

    Article  PubMed  CAS  Google Scholar 

  29. Kieta D, McCammon A, Holman W, Nielson V (2003) Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 96: 956–958

    Article  PubMed  Google Scholar 

  30. Pivalizza E (2002) Monitoring of hirudin therapy with the thromboelastograph. J Clin Anesth 14: 456–458

    Article  PubMed  CAS  Google Scholar 

  31. Taketomi T, Szlam F, Vinten-Johansen J et al. (2007) Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagul Fibrinolysis 18: 761–767

    Article  PubMed  CAS  Google Scholar 

  32. Casserly I, Kereiakes D, Gray W (2004) Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res 113: 115–121

    Article  PubMed  CAS  Google Scholar 

  33. Cho L, Kottke-Marchant K, Lincoff A (2003) Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentration. Am J Cardiol 91: 1110–1112

    Article  PubMed  Google Scholar 

  34. Welsby I, Stafford-Smith M (2004) Monitoring direct thrombin inhibitors: time for standardization (comment). Anesthesiology 101: 1048–1049

    Article  PubMed  Google Scholar 

  35. Harder S, Graff J, Klinkhardt U et al. (2004) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost 91: 1137–1145

    PubMed  CAS  Google Scholar 

  36. Selleng K, Greinacher A (2005) Heparin-induzierte Thrombozytepenie in der Intensivmedizin. Intensivmedizin Update 1: 1–16

    Article  Google Scholar 

  37. Warkentin T, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 311S–337S

    Article  PubMed  CAS  Google Scholar 

  38. Muslimani A, Ricaurte B, Daw H (2007) Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Haematol 82: 652–655

    Article  CAS  Google Scholar 

  39. Warkentin T, Hayward C, Boshkowv L (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84: 3691–3693

    PubMed  CAS  Google Scholar 

  40. Greinacher A, Vögel H, Janssen U (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100: 587–590

    PubMed  CAS  Google Scholar 

  41. Lubenow N, Eichler P, Lietz T et al. (2004) Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104: 3072–3077

    Article  PubMed  CAS  Google Scholar 

  42. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 311S-337S

    Article  PubMed  CAS  Google Scholar 

  43. Stribling W, Slaughter TF, Houly T, Sane D (2007) Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J 153: 900–906

    Article  PubMed  CAS  Google Scholar 

  44. Wan C, Warner M, Varennes B de et al. (2006) Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy. Ann Thorac Surg 82: 21–27

    Article  PubMed  Google Scholar 

  45. Pappalardo F, Crescnzi G, Franco A, Zangrillo A (2006) Early heparin-induced thrombocytopaenia (HIT) after cardiac surgery. Eur J Anaesthesiol 23: 806–814

    Article  PubMed  CAS  Google Scholar 

  46. Everett B, Yeh R, Foo S et al. (2007) Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 83: 592–597

    Article  PubMed  Google Scholar 

  47. Kress D, Aronson S, McDonald M et al. (2007) Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 83: 1737–1743

    Article  PubMed  Google Scholar 

  48. Kuitunen A, Suojaranta-Ylinen R, Raivio P et al. (2007) Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Thorac Cardiovasc Surg 21: 18–22

    Google Scholar 

  49. Warkentin T, Kelton J (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344: 1286–1292

    Article  PubMed  CAS  Google Scholar 

  50. Pötsch B, Klovekorn W, Madlener K (2000) Use of heparin during cardiopulmonary bypass in patients with history of heparin-induced thrombocytopenia. N Engl J Med 343: 515–519

    Article  Google Scholar 

  51. Edwards J, Hamby J, Worrall N (2003) Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 75: 1622–1624

    Article  PubMed  Google Scholar 

  52. Furukawa K, Ohteki H, Hirahara K et al. (2001) The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 122: 1255–1256

    Article  PubMed  CAS  Google Scholar 

  53. Gasparovic H, Nathan N, Fitzgerald D, Aranki S (2004) Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 78: 89–91

    Article  Google Scholar 

  54. Reichert M, MacGregor D, Kincaid E, Dolinski S (2003) Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 37: 652–654

    Article  PubMed  Google Scholar 

  55. Kurup V, Transue S, Wu Y et al. (2006) Cardiac surgery in a patient with heparin-induced thrombocytopenia – cautions with use of the direct thrombin inhibitor argatroban. Conn Med 70: 245–250

    PubMed  Google Scholar 

  56. Nuttall G, Oliver W, Santarach P (2003) Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 96: 344–350

    Article  PubMed  Google Scholar 

  57. Koster A, Hansen R, Kuppe H et al. (2000) Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 14: 243–248

    Article  PubMed  CAS  Google Scholar 

  58. Koster A, Spiess B, Chew DP (2004) Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93: 356–359

    Article  PubMed  CAS  Google Scholar 

  59. Vasquez J, Vichiendilokkul A, Mahmood S, Baciewicz F (2002) Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 74: 2177–2179

    Article  PubMed  Google Scholar 

  60. Dyke CK, Smedira N, Koster A et al. (2006) A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131: 533–539

    Article  PubMed  CAS  Google Scholar 

  61. Smedira N, Dyke CK, Koster A et al. (2006) Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131: 686–692

    Article  PubMed  CAS  Google Scholar 

  62. Davis Z, Anderson R, Short D (2003) Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 74: 2177–2179

    Google Scholar 

  63. Bott J, Reddy B, Krick S (2003) Bivalirudin in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 76: 273–275

    Article  PubMed  Google Scholar 

  64. Aouifi A, Blanc P, Piriou V (2001) Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 71: 678–683

    Article  PubMed  CAS  Google Scholar 

  65. Warkentin TE, Greinacher A (2003) Heparin-induced thrombopenia and cardiac surgery. Ann Thorac Surg 76: 2121–2131

    Article  PubMed  Google Scholar 

  66. Merry AF, Raudkivi PJ, Middleton NG et al. (2004) Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77: 925–931; discussion 931

    Article  PubMed  Google Scholar 

  67. Riess F, Poetszsch B, Madlener K et al. (2007) Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. Throrac Cardiovasc Surg 55: 233–238

    Article  Google Scholar 

  68. Saravanan P, Rege K, Falter F (2007) Use of continuous venovenous hemofiltration for reversal of anticoagulation with lepirudin post-cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia after heart transplantation. J Thorac Cardiovasc Surg 21: 269–272

    Google Scholar 

  69. Koster A, Merkle F, Hansen R (2000) Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 91: 265–269

    Article  PubMed  CAS  Google Scholar 

  70. Lubenow N, Selleng K, Wollert H (2003) Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 75: 577–579

    Article  PubMed  Google Scholar 

  71. Martin M, Kloecker G, Laber D (2006) Argatroban for anticoagulation during cardiac surgery. Eur J Haematol 78: 161–166

    Google Scholar 

  72. Cormack G, Kaufman L (2007) Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report. J Med Case Rep 1: 1–13

    Article  Google Scholar 

  73. Magnani HN, Beijering R, Cate H ten (1997) Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R (ed) New anticoagulants for the cardiovascular patient. Hanley & Belfus, Philadelphia, pp 487–500

  74. Walls J, Curtis J, Silver D et al. (1992) Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg 53: 787–791

    Article  PubMed  CAS  Google Scholar 

  75. Koster A, Meyer O, Fischer T (2001) One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 122: 1254–1255

    Article  PubMed  CAS  Google Scholar 

  76. Schreiber C, Dietrich W, Braun S et al. (2006) Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies. Clin Res Cardiol 95: 379–382

    Article  PubMed  Google Scholar 

  77. Klenner A, Lubenow N, Ratschke R, Greinacher A (2004) Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 91: 719–724

    PubMed  CAS  Google Scholar 

  78. Dyke P, Russo P, Mureebe L (2005) Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Pediatr Anesthesia 15: 328–333

    Article  Google Scholar 

  79. Malherbe S, Tsui B, Stobart K, Koller J (2004) Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 100: 443–445

    Article  PubMed  Google Scholar 

  80. Dyke P, Russo P, Mureebe L et al. (2005) Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Pediatric Anesthesia 15: 328–333

    Article  PubMed  Google Scholar 

  81. Hursting M, Dubb J, Verme-Gibboney C (2006) Argatroban anticoagulation in pediatric patients. J Pediatr Hematol Oncol 28: 4-10

    Article  PubMed  CAS  Google Scholar 

  82. Powner DJ, Hartwell EA, Hoots WK (2005) Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery 57: 823–831; discussion 823–831

    Article  PubMed  Google Scholar 

  83. Ibbotson SH, Grant PJ, Kerry R et al. (1991) The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost 65: 64–66

    PubMed  CAS  Google Scholar 

  84. Amin DM, Mant TG, Walker SM et al. (1997) Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers. Thromb Haemost 77: 127–132

    PubMed  CAS  Google Scholar 

  85. Bove CM, Casey B, Marder VJ (1996) DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 75: 471–475

    PubMed  CAS  Google Scholar 

  86. Butler KD, Dolan SL, Talbot MD, Wallis RB (1993) Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coagul Fibrinolysis 4: 459–464

    Article  PubMed  CAS  Google Scholar 

  87. Irani MS, White HJ Jr, Sexon RG (1995) Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 75: 422–423

    Article  PubMed  CAS  Google Scholar 

  88. Fareed J, Walenga JM, Pifarre R et al. (1991) Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. Haemostasis 21 [Suppl 1]: 64–72

  89. Oh K, Akers W, Lewis D et al. (2006) Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 26: 569–577

    Article  PubMed  Google Scholar 

  90. Stratmann G, Silva A di, Tseng E et al. (2004) Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 98: 1635–1639

    Article  PubMed  Google Scholar 

  91. Irani M, White H, Sexon G (1995) Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 75: 422–423

    Article  PubMed  CAS  Google Scholar 

  92. Diehl K, Romisch J, Hein B et al. (1995) Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis 25: 182–192

    PubMed  CAS  Google Scholar 

  93. Novak G, Bucha E (1995) Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thromb Res 80: 317–325

    Article  Google Scholar 

  94. Yee AJ, Kuter DJ (2006) Successful recovery after an overdose of argatroban. Ann Pharmacother 40: 336–339

    Article  PubMed  Google Scholar 

  95. Murray PT, Reddy BV, Grossman EJ et al. (2004) A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66: 2446–2453

    Article  PubMed  CAS  Google Scholar 

  96. Young G, Yonekawa K, Nakagawa P et al. (2007) Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux argatroban, and bivalirudin ex vivo as measured using thrombelastography. Blood Coagul Fibrinolysis 18: 547–553

    Article  PubMed  CAS  Google Scholar 

  97. Koster A, Chew DP, Gründel M et al. (2003) An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 96: 1316–1319

    Article  PubMed  CAS  Google Scholar 

  98. Mann M, Tseng EE, Ratcliff M et al. (2005) Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 24: 222–225

    Article  PubMed  Google Scholar 

  99. Kozek-Langenecker S, Fries D, Gütl M et al. (2005) Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine. Anaesthesist 54: 476–484

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abteilung für Spezielle Anästhesie und Schmerztherapie, Univ.-Klinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Medizinische Universität Wien, Währinger Gürtel 18–20, 1090, Wien, Österrreich

    S.A. Kozek-Langenecker

Authors
  1. S.A. Kozek-Langenecker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S.A. Kozek-Langenecker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kozek-Langenecker, S. Direkte Thrombininhibitoren. Anaesthesist 57, 597–606 (2008). https://doi.org/10.1007/s00101-008-1347-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00101-008-1347-5

Schlüsselwörter

Keywords

Search

Navigation